Docoh
Loading...

BLUE Bluebird bio

News

From Benzinga Pro
Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe
21 Oct 21
Biotech, News, Health Care, Small Cap, General
bluebird bio To Withdraw Marketing Authorization For SKYSONA From EU And Withdraw Marketing Applicatino For SKYSONA From MHRA
21 Oct 21
Biotech, Government, Regulations, General
On October 21, 2021, bluebird bio, Inc. announced that as part of the winding down of its operations in Europe, it will withdraw its regulatory marketing authorization for SKYSONA from the European Union, and its
bluebird bio Highlights Filing By Its 2seventy Bio Related To Spin Off
8 Oct 21
News, Asset Sales
bluebird bio, Inc. (NASDAQ:BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This Form 10 reflects bluebird bio’s
What 6 Analyst Ratings Have To Say About bluebird bio
22 Sep 21
Analyst Ratings
Analysts have provided the following ratings for bluebird bio (NASDAQ:BLUE) within the last quarter:
Mizuho Maintains Buy on bluebird bio, Lowers Price Target to $23
22 Sep 21
News, Price Target, Analyst Ratings
Mizuho analyst Difei Yang maintains bluebird bio (NASDAQ:BLUE) with a Buy and lowers the price target from $29 to $23.
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)
Bluebird Bio Files US Application For β-thalassemia Gene Therapy
22 Sep 21
Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
8 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7)
The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More
4 Sep 21
Small Cap, Media
This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall.
Stocks That Hit 52-Week Lows On Friday
20 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug 21
Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
10 Aug 21
Options
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021
10 Aug 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Stocks That Hit 52-Week Lows On Tuesday
10 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows.
Canaccord Genuity Downgrades bluebird bio to Hold, Lowers Price Target to $20
10 Aug 21
News, Downgrades, Price Target, Analyst Ratings
Canaccord Genuity analyst John Newman downgrades bluebird bio (NASDAQ:BLUE) from Buy to Hold and lowers the price target from $86 to $20.
Goldman Sachs Downgrades bluebird bio to Neutral, Lowers Price Target to $23
10 Aug 21
News, Downgrades, Price Target, Analyst Ratings
Goldman Sachs analyst Salveen Richter downgrades bluebird bio (NASDAQ:BLUE) from Buy to Neutral and lowers the price target from $63 to $23.
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)
Wells Fargo Downgrades bluebird bio to Equal-Weight, Lowers Price Target to $25
10 Aug 21
News, Downgrades, Price Target, Analyst Ratings
Wells Fargo analyst Yanan Zhu downgrades bluebird bio (NASDAQ:BLUE) from Overweight to Equal-Weight and lowers the price target from $60 to $25.
68 Biggest Movers From Yesterday
10 Aug 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers

Press releases

From Benzinga Pro
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
18 Oct 21
Press Releases
bluebird bio, Inc. (NASDAQ:BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect
bluebird bio Provides Update on Upcoming Planned Business Separation
8 Oct 21
Press Releases
- Company shares detail on stock distribution ratio and planned cash allocation - - New board members appointed - bluebird bio, Inc. (NASDAQ:BLUE) today announced the filing by 2seventy bio of an updated Form 10
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
21 Sep 21
Press Releases
BLA submission based on data from Phase 1/2 and Phase 3 Northstar studies, which represent more than 220 patient-years of experience with beti-cel bluebird bio, Inc. (NASDAQ:BLUE) today announced it has completed the
bluebird bio Secures $75 Million in Private Placement Equity Financing
8 Sep 21
Press Releases
Proceeds to support both bluebird bio and 2seventy bio's pipeline of novel cell therapy programs Business separation of bluebird and 2seventy expected to be completed in October 2021 bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
7 Sep 21
Press Releases
Gina Consylman appointed chief financial officer, severe genetic disease Marcela Maus named to bluebird bio board of directors bluebird bio and 2seventy bio to hold investor events in September in advance of
BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
13 Aug 21
Press Releases
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc.
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
9 Aug 21
Press Releases
- On track to complete planned business separation in 4Q 2021; each company launching with approximately 24 months of runway following separation – - Severe genetic disease (SGD) business to scale back operations in
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
5 Aug 21
Press Releases
bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Aug 21
Press Releases
bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 85,000 shares of common stock and
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
28 Jul 21
Press Releases
Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong